Bausch Health Companies Inc. (NYSE:BHC) went down by -1.82% from its latest closing price compared to the recent 1-year high of $34.80. The company’s stock price has collected -1.95% of loss in the last five trading sessions. Press Release reported on 09/13/21 that Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network(R) (NCCN) Guidelines for Prostate Cancer
Is It Worth Investing in Bausch Health Companies Inc. (NYSE :BHC) Right Now?
Plus, the 36-month beta value for BHC is at 1.69. Opinions of the stock are interesting as 8 analysts out of 15 who provided ratings for Bausch Health Companies Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $36.23, which is $7.42 above the current price. BHC currently public float of 342.93M and currently shorts hold a 5.29% ratio of that float. Today, the average trading volume of BHC was 2.21M shares.
BHC’s Market Performance
BHC stocks went down by -1.95% for the week, with a monthly jump of 3.99% and a quarterly performance of -7.22%, while its annual performance rate touched 80.14%. The volatility ratio for the week stands at 2.62% while the volatility levels for the past 30 days are set at 2.56% for Bausch Health Companies Inc.. The simple moving average for the period of the last 20 days is 0.24% for BHC stocks with a simple moving average of 1.45% for the last 200 days.
Analysts’ Opinion of BHC
Many brokerage firms have already submitted their reports for BHC stocks, with BofA Securities repeating the rating for BHC by listing it as a “Underperform.” The predicted price for BHC in the upcoming period, according to BofA Securities is $27 based on the research report published on March 24th of the current year 2021.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see BHC reach a price target of $42, previously predicting the price at $26. The rating they have provided for BHC stocks is “Outperform” according to the report published on February 17th, 2021.
Piper Sandler gave a rating of “Neutral” to BHC, setting the target price at $30 in the report published on January 22nd of the current year.
BHC Trading at 0.98% from the 50-Day Moving Average
After a stumble in the market that brought BHC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.64% of loss for the given period.
Volatility was left at 2.56%, however, over the last 30 days, the volatility rate increased by 2.62%, as shares surge +4.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.12% lower at present.
During the last 5 trading sessions, BHC fell by -1.95%, which changed the moving average for the period of 200-days by +49.50% in comparison to the 20-day moving average, which settled at $28.65. In addition, Bausch Health Companies Inc. saw 37.79% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at BHC starting from VON ESCHENBACH ANDREW C., who purchase 1,400 shares at the price of $25.94 back on Aug 05. After this action, VON ESCHENBACH ANDREW C. now owns 38,647 shares of Bausch Health Companies Inc., valued at $36,316 using the latest closing price.
DE SCHUTTER RICHARD U, the Director of Bausch Health Companies Inc., purchase 10,000 shares at $25.01 during a trade that took place back on Aug 04, which means that DE SCHUTTER RICHARD U is holding 317,109 shares at $250,123 based on the most recent closing price.